Trinity Biotech plc Asset Resilience Ratio

Latest as of September 2023: 29.53%

Trinity Biotech plc asset resilience ratio. Trinity Biotech plc (TRIB) has an Asset Resilience Ratio of 29.53% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Trinity Biotech plc (TRIB) defensive interval to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$18.78 Million
Cash + Short-term Investments

Total Assets

$63.60 Million
All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Trinity Biotech plc (1997–2020)

Asset resilience ratio of Trinity Biotech plc from 1997 to 2020. This chart shows how Trinity Biotech plc's Asset Resilience Ratio has changed over time. Read how much debt does Trinity Biotech plc carry for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Trinity Biotech plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Trinity Biotech plc's balance sheet.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $18.78 Million 29.53%
Total Liquid Assets $18.78 Million 29.53%

Asset Resilience Insights

  • Very High Liquidity: Trinity Biotech plc maintains exceptional liquid asset reserves at 29.53% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Trinity Biotech plc Industry Peers by Asset Resilience Ratio

Compare Trinity Biotech plc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
HOB Biotech Group Corp Ltd
SHG:688656
Medical Devices 2.62%
L&C Bio Co. Ltd
KQ:290650
Medical Devices 2.14%
Applied BioCode
TW:6598
Medical Devices 9.75%
Oncosil Medical Ltd
AU:OSL
Medical Devices 0.00%
Cleo Diagnostics Ltd
AU:COV
Medical Devices 94.64%
Radiant Innovation
TWO:3373
Medical Devices 0.82%
Impedimed Ltd
AU:IPD
Medical Devices 46.15%
Memphasys Ltd
AU:MEM
Medical Devices 0.00%

Trinity Biotech plc Asset Resilience Ratio by Year (1997–2020)

Trinity Biotech plc asset resilience ratio by year from 1997 to 2020. The table below shows the annual Asset Resilience Ratio data for Trinity Biotech plc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2020-12-31 0.00% $0.00 $130.40 Million --
2019-12-31 0.89% $1.17 Million $131.07 Million -14.60pp
2018-12-31 15.49% $23.42 Million $151.24 Million -2.19pp
2017-12-31 17.67% $34.04 Million $192.62 Million -8.70pp
2015-12-31 26.37% $94.66 Million $358.96 Million +25.60pp
2014-12-31 0.77% $1.88 Million $242.84 Million -5.09pp
2013-12-31 5.86% $13.28 Million $226.49 Million -26.30pp
2012-12-31 32.17% $63.50 Million $197.41 Million -7.43pp
2011-12-31 39.59% $67.90 Million $171.50 Million +5.03pp
2010-12-31 34.56% $55.60 Million $160.87 Million +33.50pp
2009-12-31 1.06% $1.40 Million $132.44 Million -0.49pp
2008-12-31 1.54% $2.00 Million $129.51 Million -0.54pp
2007-12-31 2.08% $4.50 Million $215.98 Million -4.14pp
2006-12-31 6.22% $15.50 Million $249.13 Million +3.53pp
2005-12-31 2.69% $4.96 Million $184.60 Million +2.47pp
1998-12-31 0.22% $100.00K $45.00 Million -5.47pp
1997-12-31 5.69% $1.40 Million $24.60 Million --
pp = percentage points

About Trinity Biotech plc

NASDAQ:TRIB USA Medical Devices
Market Cap
$5.23 Million
Market Cap Rank
#28412 Global
#5852 in USA
Share Price
$6.43
Change (1 day)
-2.02%
52-Week Range
$0.30 - $13.38
All Time High
$67.65
About

Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually tr… Read more